Alain Ravaud
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Renal cell carcinoma treatment
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- Renal cell carcinoma treatment 159
- Oncology 110
- Cancer Immunotherapy and Biomarkers 43
- Colorectal Cancer Treatments and Studies 17
- Co-authors
- Bernard J. Escudier (59 shared papers)Sergio Bracarda (15 shared papers)Lucile Capuron (6 shared papers)Stéphane Marie. Oudard (22 shared papers)Robert John Motzer (28 shared papers)Christine Chevreau (28 shared papers)Sylvie Négrier (24 shared papers)Camillo Porta (16 shared papers)
- Journals
- Annals of Oncology (44 papers)European Journal of Cancer (29 papers)Journal of Clinical Oncology (17 papers)European Urology (16 papers)Clinical Cancer Research (8 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
Alain Ravaud
326 papers receiving 33.9k citations
Alain Ravaud's Hit Papers
Peers
Comparison fields: 5 of 152
- Pulmonary and Respiratory Medicine 16.8k
- Oncology 11.9k
- Cancer Research 5.6k
- Biological Psychiatry 853
- Behavioral Neuroscience 603
Countries citing papers authored by Alain Ravaud
This map shows the geographic impact of Alain Ravaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Ravaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Ravaud more than expected).
Fields of papers citing papers by Alain Ravaud
This network shows the impact of papers produced by Alain Ravaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Ravaud. The network helps show where Alain Ravaud may publish in the future.
Co-authors
The 25 scholars most cited alongside Alain Ravaud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 334 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 4815 |
| 2 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 3 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Hit paper breakdown → | 2008 | 2538 |
| 4 | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Hit paper breakdown → | 2007 | 1845 |
| 5 | Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2017 | 1141 |
| 6 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 7 | Phase 3 trial of everolimus for metastatic renal cell carcinoma Hit paper breakdown → | 2010 | 983 |
| 8 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 9 | Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 1998 | 783 |
| 10 | Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival Hit paper breakdown → | 2010 | 685 |
| 11 | Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 676 |
| 12 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy Hit paper breakdown → | 2016 | 592 |
| 13 | Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2013 | 571 |
| 14 | Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study Hit paper breakdown → | 2017 | 511 |
| 15 | Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial Hit paper breakdown → | 2017 | 485 |
| 16 | Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial Hit paper breakdown → | 2019 | 457 |
| 17 | 2002 | 410 | |
| 18 | Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2021 | 397 |
| 19 | Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study Hit paper breakdown → | 2017 | 391 |
| 20 | 2012 | 358 |
About Alain Ravaud
Alain Ravaud is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery and Molecular Biology, having authored 334 papers that have together received 34.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (159 papers), Renal and related cancers (54 papers), Bladder and Urothelial Cancer Treatments (44 papers), Cancer Immunotherapy and Biomarkers (43 papers), Cancer Genomics and Diagnostics (36 papers), Colorectal Cancer Treatments and Studies (17 papers), Urinary and Genital Oncology Studies (16 papers) and Economic and Financial Impacts of Cancer (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (16.8k citations), Oncology (11.9k citations), Cancer Research (5.6k citations), Biological Psychiatry (853 citations) and Behavioral Neuroscience (603 citations). Alain Ravaud has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Bernard J. Escudier, Sergio Bracarda, Lucile Capuron, Stéphane Marie. Oudard, Robert John Motzer, Christine Chevreau, Sylvie Négrier, Camillo Porta, Robert Dantzer and Viktor Grünwald. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Journal of Clinical Oncology, European Urology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.